Table 2 Treatment options for HAE attacks in the USA approved by the Food and Drug Administration (FDA) [12,13,14,15,16,17,18,19,20,21, 25,26,27,28,29]
From: Bradykinin-induced angioedema in the emergency department
Drug | Indication |
|---|---|
Plasma-derived C1-INH (Berinert) | Acute abdominal, facial or laryngeal HAE attacks in adult and paediatric patients |
Plasma-derived C1-INH (Cinryze) | Routine prophylaxis against angioedema attacks in adults, adolescents and paediatric patients (6 years of age and older) with HAE |
Recombinant C1-INH (Ruconest) | Acute attacks of HAE in adult and adolescent patients with HAE |
Icatibant, synthetic bradykinin B2 receptor antagonist (Firazyr) | Acute attacks of HAE in adults 18 years of age and older |
Ecallantide, synthetic kallikrein inhibitor (Kalbitor) | Acute attacks of HAE in patients 12 years of age and older |
FFP | Deficiency of coagulation factors or plasma protein, when alternative therapies are not available |